Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets
This product will be manufactured at Lupin’s Pithampur facility in India
This product will be manufactured at Lupin’s Pithampur facility in India
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
The product basket increased to 1800 medicines and 285 Surgical Equipment
Subscribe To Our Newsletter & Stay Updated